Alnylam’s longer-term RNAi treatment lowers blood pressure in mid-stage study
One to two doses of an RNA interference treatment developed by Alnylam Pharmaceuticals reduced blood pressure for six months in a mid-stage clinical trial, according …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.